Literature DB >> 19760282

Chronic therapy with citalopram decreases regional cerebral glucose utilization in OBX, and not sham-operated, rats: an autoradiographic study.

Ivan Skelin1, Hiroki Sato, Tomislav Kovacević, Mirko Diksic.   

Abstract

RATIONALE: Chronic treatment with the selective serotonin reuptake inhibitor, citalopram, normalizes several behavioral and neurochemical abnormalities in the olfactory bulbectomized (OBX) rat model of depression.
OBJECTIVE: To assess the changes in regional cerebral glucose utilization (rCGU) following chronic treatment with citalopram in OBX and sham-operated rats.
METHODS: Male Sprague Dawley rats (160-190 g) were used. Two weeks following the surgeries, the rats were implanted with osmotic minipumps which delivered 10 mg/kg/day of citalopram (the sham-CTP and OBX-CTP groups) or saline (to the sham-SAL and OBX-SAL groups) for 2 weeks. Following the treatment, the rates of rCGU were determined in 43 brain regions using 2-[(14)C]deoxyglucose (2-[(14)C]DG) autoradiography.
RESULTS: The general linear model statistical analysis revealed significantly lower rCGU in the OBX-SAL group compared to the sham-SAL group in the medial prefrontal cortex and the median forebrain bundle. The sham-CTP group had significantly lower rCGU relative to the sham-SAL group in the medial prefrontal cortex. The OBX-CTP group had significantly lower rCGU than the OBX-SAL group in the anterior olfactory nucleus, orbitofrontal cortex, frontal cortex, anterior cingulate cortex, visual cortex, and substantia nigra--pars reticulata. The rCGU in the OBX-CTP group was significantly lower than that in the sham-CTP group in the anterior olfactory nucleus, orbitofrontal cortex, visual cortex, and substantia nigra--pars reticulata.
CONCLUSION: The results imply that chronic citalopram treatment, shown previously to result in behavioral normalization in OBX rats, establishes a new pattern of rCGU, rather than normalizing it to the pattern of the sham-CTP rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760282     DOI: 10.1007/s00213-009-1659-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

Review 1.  A review of functional neuroimaging in mood disorders: positron emission tomography and depression.

Authors:  S H Kennedy; M Javanmard; F J Vaccarino
Journal:  Can J Psychiatry       Date:  1997-06       Impact factor: 4.356

Review 2.  Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI.

Authors:  M Jueptner; C Weiller
Journal:  Neuroimage       Date:  1995-06       Impact factor: 6.556

3.  Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei.

Authors:  N Bel; F Artigas
Journal:  Synapse       Date:  1993-11       Impact factor: 2.562

4.  Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression.

Authors:  Mario Liotti; Helen S Mayberg; Scott McGinnis; Stephen L Brannan; Paul Jerabek
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

5.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

Authors:  H S Mayberg; S K Brannan; J L Tekell; J A Silva; R K Mahurin; S McGinnis; P A Jerabek
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

6.  Depression and recovery of metabolic activity in rat visual system after eye removal.

Authors:  R M Cooper; G A Thurlow
Journal:  Exp Neurol       Date:  1985-08       Impact factor: 5.330

7.  Cerebral metabolic effects of fluoxetine, fluvoxamine, paroxetine and sertraline in the conscious rat.

Authors:  Ulderico Freo; Antonio Merico; Mario Ermani; Carlo Ori
Journal:  Neurosci Lett       Date:  2008-03-18       Impact factor: 3.046

8.  Limbic-frontal circuitry in major depression: a path modeling metanalysis.

Authors:  D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

9.  Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.

Authors:  Atsuko Nagano-Saito; Takashi Kato; Yutaka Arahata; Yukihiko Washimi; Akinori Nakamura; Yuji Abe; Takako Yamada; Katsushige Iwai; Kentaro Hatano; Yasuhiro Kawasumi; Teruhiko Kachi; Alain Dagher; Kengo Ito
Journal:  Neuroimage       Date:  2004-06       Impact factor: 6.556

10.  Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat.

Authors:  D Stanic; D I Finkelstein; D W Bourke; J Drago; M K Horne
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

View more
  2 in total

1.  Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.

Authors:  Jason Shumake; Rene A Colorado; Douglas W Barrett; F Gonzalez-Lima
Journal:  Brain Res       Date:  2010-05-12       Impact factor: 3.252

2.  FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors.

Authors:  Frederick A Schroeder; Daniel B Chonde; Misha M Riley; Christian K Moseley; Michael L Granda; Colin M Wilson; Florence F Wagner; Yan-Ling Zhang; Jennifer Gale; Edward B Holson; Stephen J Haggarty; Jacob M Hooker
Journal:  Neurosci Lett       Date:  2013-06-25       Impact factor: 3.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.